Therapeutic Action
Long-lasting lactation inhibitor
PDF page 69
Loading InternPractice…
Drug reference
Long-lasting lactation inhibitor
PDF page 69
Inhibition of lactation or suppression of established lactation in case of intrauterine foetal death or neonatal death
PDF page 69
Do not administer to patients with postpartum hypertension or psychosis, preeclampsia, valvulopathy, and history of pulmonary, retroperitoneal or pericardial fibrosis. May cause: hypotension, valvulopathy, dizziness, headache, nausea, drowsiness, hallu cinations. Do not combine with chlorpromazine, haloperidol, metoclopramide, promethazine (effect of cabergoline antagonised), methylergometrine (risk of vasoconstriction and hypertensive crisis), and macrolides (effect of cabergoline increased). Pregnancy: CONTRA-INDICATED
PDF page 69
0.5 mg scored tablet
PDF page 69
Lactation inhibition 1 mg single dose on the first day post-partum Lactation suppression 0.25 mg every 12 hours for 2 days
PDF page 69
The use of cabergoline is not recommended to inhibit lactation in women who chose to not breastfeed: it is not justified to expose women to the adverse effects of cabergoline, lactation will stop spontaneously. Cabergoline is not included in the WHO list of essential medicines. Cabergoline is a dopamine agonist also used in the treatment of Parkinson’s disease.
PDF pages 69, 70
– – Below 25 °C
PDF page 70